Doctor Jeanmarie Guenot’s Pedigree Reignited in Amphivena Therapeutics

JeanMarie Guenot, President and Chief Executive Officer of Amphivena Therapeutics, is proving to the world that her impeccable attainments before her present appointment were not accidental. Those who thought she will not be able to replicate her past exploits in Amphivena Therapeutics are beginning to have a change of mind.

Before Jeanmarie Guenot joined Amphivena Therapeutics, she was already a success story, a PhD and MD holder from the University of California and the University of Pennsylvania respectively. She has seen and experienced all that is available in the pharmaceutical and biotechnology industry having worked with multiple public and private companies in all aspects of cancer research. Several media outlets including, Market Wired, Reuters and Yahoo keep highlighting some of Guenot’s accomplishments.

Guenot’s exploits could be traced from her time with Atlas Venture handling venture capital investments. She also spent quality time at Hoffman LaRoache where she worked as a scientist in the pre-clinical research and development department. Hoffman LaRoache, as a company, focuses on producing drugs for the purpose of eliminating metabolic diseases.

Read more: Collaboration to Advance T-Cell Engagement Therapies

Just before she moved to Amphivena Therapeutics, she built and ran SKS Ocular from scratch to an enviable height. SKS Ocular is an ophthalmic incubator company that specializes on dry AMD including sustained release ocular drug delivery technologies for macular degeneration, ocular inflammation and glaucoma.

Talking about her exploits in the capacity of CEO and President of Amphivena Therapeutics, they are numerous. Recently, the Food and Drug Administration (FDA) approved an investigatory application for a new drug referred to as AMV564, an Amphivena Therapeutics proprietary T-cell that helps exterminate cancer cells. This new drug will provide another effective treatment option for AML patients. In other words, doctors will now have at their disposal a therapeutic option for AML patients.

Amphivena Therapeutics remains focus on stopping blood cancers using therapies that harness the patient’s immune system in getting rid of tumor cells. The company on through its able leadership is taking advantage of every opportunity to join forces with multiple alliances in the industry as the search for the better treatment options for patients continues.

The good works of JeanMarie Guenot deserve commendation for still giving hope to thousands of patients living with cancer even though she has been at it for decades.

Leave a Reply

Your email address will not be published. Required fields are marked *